PMID- 35834427
OWN - NLM
STAT- MEDLINE
DCOM- 20220718
LR  - 20220729
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 23
DP  - 2022 Jul 14
TI  - Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple 
      Prior Therapies: A Case Series.
PG  - e936505
LID - 10.12659/AJCR.936505 [doi]
AB  - BACKGROUND Numerous treatment options are available for patients with multiple 
      myeloma (MM). Because of the course of the disease, most patients will experience 
      serial relapse or the MM will become refractory to most of these treatments, 
      leaving patients with few or no treatment options over time. Selinexor, a 
      treatment with a novel mechanism of action, is an oral selective inhibitor of 
      nuclear export (SINE) compound that blocks exportin 1, the major nuclear exporter 
      of tumor suppressor proteins. CASE REPORT In this case series, we report on 
      treatment with the weekly oral administration of selinexor combined with 
      bortezomib and dexamethasone (XVd) in 3 patients from Argentina who were heavily 
      treated (5-7 prior therapies) for MM that relapsed or was refractory to each 
      previous treatment. Two patients had the high-risk cytogenetic abnormality 
      del(17p). All 3 patients experienced efficacy with XVd reaching a best response 
      of partial response or very good partial response. These responses were 
      consistent with those of patients from the BOSTON study who were treated with XVd 
      but were less heavily pretreated (1-3 prior therapies) and had a shorter median 
      time since diagnosis of MM (7 years vs 3.7 years). The 3 patients experienced 
      adverse events (AEs) that included nausea, thrombocytopenia, asthenia, and 
      fatigue, which were similar to the most commonly reported AEs associated with 
      selinexor treatment. CONCLUSIONS With its oral administration, novel mechanism of 
      action, and responses in heavily pretreated patients, selinexor may help to 
      address an important clinical need in the treatment of patients with 
      relapsed/refractory MM.
FAU - Remaggi, Guillermina
AU  - Remaggi G
AUID- ORCID: 0000-0002-6320-8867
AD  - Department of Hematology, Fundaleu, Buenos Aires, Argentina.
FAU - Ochoa, Paola A
AU  - Ochoa PA
AD  - Department of Hematology, Instituto Alexander Fleming, Buenos Aires, Argentina.
FAU - Garate, Gonzalo M
AU  - Garate GM
AD  - Department of Hematology, Hospital Aleman, Buenos Aires, Argentina.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220714
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
RN  - 0 (Hydrazines)
RN  - 0 (Triazoles)
RN  - 31TZ62FO8F (selinexor)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Argentina
MH  - Dexamethasone
MH  - Humans
MH  - Hydrazines
MH  - *Multiple Myeloma/drug therapy/pathology
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Triazoles
PMC - PMC9295189
COIS- Conflict of interest: None declared
EDAT- 2022/07/15 06:00
MHDA- 2022/07/19 06:00
PMCR- 2022/07/14
CRDT- 2022/07/14 13:22
PHST- 2022/07/14 13:22 [entrez]
PHST- 2022/07/15 06:00 [pubmed]
PHST- 2022/07/19 06:00 [medline]
PHST- 2022/07/14 00:00 [pmc-release]
AID - 936505 [pii]
AID - 10.12659/AJCR.936505 [doi]
PST - epublish
SO  - Am J Case Rep. 2022 Jul 14;23:e936505. doi: 10.12659/AJCR.936505.